India to force pharmaceutical plants to upgrade after fatal cough syrup crisis

Following a spate of fatal incidents tied to cough syrups, the Indian government is preparing directives forcing pharmaceutical companies to upgrade manufacturing facilities. Inspections will be mandated, compliance timelines tightened, and penalties increased for violators. The move is aimed at restoring public trust and strengthening drug safety regulations. Some companies under scrutiny may face financial strain from retrofit costs. The development is expected to have implications across the pharmaceutical sector in India.